Life Sciences Microbiome Therapeutic Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Microbiome Therapeutic Platforms
1.1 - About Life Sciences Microbiome Therapeutic Platforms sector
Companies in the Life Sciences Microbiome Therapeutic Platforms category discover, engineer, and commercialize microbiome-based drugs, including live biotherapeutic products and microbial consortia that modulate host pathways. They provide end-to-end capabilities from target discovery and preclinical validation to GMP manufacturing and clinical development, aiming to restore microbial balance and improve outcomes in infectious, gastrointestinal, metabolic, and immuno-oncology indications. Analysts researching strategic buyers in microbiome therapeutics evaluate pipelines, platforms, and manufacturing readiness.
These companies build discovery engines using metagenomics, metabolomics, and machine learning to pinpoint microbial targets, then advance live biotherapeutic formulations spanning single strains and defined consortia. They engineer probiotic chassis and bacteriophage therapies, develop microbiome‑modulating small molecules and prebiotics, and design companion diagnostics based on 16S and shotgun sequencing. Capabilities extend to anaerobic GMP manufacturing, lyophilization and stability testing, IND-enabling studies, clinical trial operations, and bioinformatics pipelines for strain banking and lot-release analytics.
Primary customers include biopharma R&D groups seeking novel assets, clinical-stage biotech sponsors progressing microbiome pipelines, and academic medical centers collaborating on translational studies. Outcomes typically include faster target validation, de-risked IND filings, scalable GMP supply for trials, and improved efficacy or reduced recurrence in CDI, IBD, and other indications. These vendors also enable partnering and licensing pathways that expand portfolios and accelerate time to proof-of-concept.
2. Buyers in the Life Sciences Microbiome Therapeutic Platforms sector
2.1 Top strategic acquirers of Life Sciences Microbiome Therapeutic Platforms companies
Pendulum
- Description: Provider of microbiome-based probiotic products designed to address gut microbiome imbalances and improve whole-body health, combining pharmaceutical-level efficacy with the safety and accessibility of probiotics.
- Key Products:
- Metabolic Daily: Daily probiotic formula promoted to improve metabolism by acting on the gut microbiome, helping users support healthier metabolic function
- Akkermansia: Targeted supplement focused on the Akkermansia strain that is advertised to improve gut health for better digestive balance
- Polyphenol Booster: Microbiome product formulated to increase antioxidants, helping protect cells from oxidative stress and support overall cellular health
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Microbiome Therapeutic Platforms sector
M&A buyer group 1: Synthetic Biology Platforms
Amyris
- Type: N/A
- Employees: ●●●●●
- Description: Provider of consumer products and science-based ingredients, offering health and wellness, clean beauty, personal care, and flavor and fragrance ingredients that are sold through e-commerce, retail channels and directly to formulators, distributors and joint-venture partners.
- Key Products:
- Zero Calorie Sugarcane-Derived Sweetener: Fermented from sugarcane to 95 % purity, delivering a zero-calorie sweet taste without bitter aftertaste and produced sustainably at scale
- Bioscience Fermentation Platform: Proprietary microbial engineering process converting plant sugars into hydrocarbon molecules, enabling large-scale production of renewable specialty ingredients for multiple consumer markets
- No Compromise Ingredient Portfolio: Range of sustainable health, beauty, flavor and fragrance molecules supplied to brand partners, offering high performance with reduced environmental impact.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Microbiome Therapeutic Platforms sector
3.1 - Buyout funds in the Life Sciences Microbiome Therapeutic Platforms sector
2.2 - Strategic buyer groups for Life Sciences Microbiome Therapeutic Platforms sector
4 - Top valuation comps for Life Sciences Microbiome Therapeutic Platforms companies
4.2 - Public trading comparable groups for Life Sciences Microbiome Therapeutic Platforms sector
Valuation benchmark group 1: Platform Biotech and Therapeutics Companies
argenx
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of antibody-based therapies focusing on treating severe autoimmune diseases, utilizing an innovative immunology platform to develop differentiated medicinal products for global markets.
- Key Products:
- Efgartigimod: An antibody therapy for immune disorders, improving symptom control in patients
- VYVGART: A first-in-class neonatal Fc receptor blocker for managing autoimmune conditions
- Immunology Innovation Program: Collaborates to accelerate novel target discovery and therapy development
- Clinical Trials: Executes global studies to validate efficacy and safety of therapeutic candidates
- Patient Support Services: Offers resources and guidance for patients using their therapies.